Cellebrite DI (CLBT) Cost of Revenue (2020 - 2026)

Cellebrite DI has reported Cost of Revenue for 7 years, with the latest figure at $25.2 million in Q2 2026.

• On a quarterly basis, Cost of Revenue rose 42.6% year-over-year to $25.2 million in Q2 2026; TTM through Jun 2026 was $87.6 million, a 28.43% increase from a year earlier, with the FY2025 full-year figure at $75.2 million, up 20.1% from the prior year.
• Cost of Revenue was $25.2 million for Q2 2026 at Cellebrite DI, up from $22.4 million in the prior quarter.
• The five-year high for Cost of Revenue was $25.2 million in Q2 2026, with the low at $11.0 million in Q1 2022.
• Average Cost of Revenue over 5 years is $16.1 million, with a median of $15.2 million recorded in 2023.
• The sharpest annual moves came in 2023 and 2026: Cost of Revenue fell 11.39% in 2023, then soared 42.6% in 2026.
• Over 5 years, Cost of Revenue stood at $12.1 million in 2022, then grew by 22.96% to $14.9 million in 2023, then advanced by 18.16% to $17.6 million in 2024, then gained by 11.73% to $19.7 million in 2025, then gained by 28.01% to $25.2 million in 2026.
• The last three Cost of Revenue figures came in at $25.2 million (Q2 2026), $22.4 million (Q1 2026), and $19.7 million (Q4 2025), per Business Quant data.